Biotech Values

[apljack]

NXTM "NxStage Reports Record Third Quarter Financial Results And Increases Financial Guidance For 2015"

(This has been one of the most boring "wait for it" investments I have in my portfolio but has FINALLY broken out. The only disappointment in the numbers is that in-center revenue has not grown YOY; the co.'s strategy has been to have its devices used in their own dialysis centers and they have aggressively opened several to fill this segment of their business. They still need to be able to break even rather than lose money!)

- Revenue Increases to $86.5 million, up 15% from Q3'14
- Home Revenue Increases to $46.5 million, up 15% from Q3'14
- Company Raises Full-Year 2015 Revenue Guidance to be between $332 and $333 million and Narrows Net Loss Guidance
- Company Hosts Financial Analyst Day and Unveils Innovation Pipeline

https://finance.yahoo.com/news/nxstage-reports-record-third-quarter-122800042.html